ANTICOAGULATION THERAPY IN NEWBORN: AN BIBLIOGRAPHIC REVIEW
DOI:
https://doi.org/10.47820/recima21.v4i12.4476Keywords:
Anticoagulantes. Coagulação sanguínea. Recém-nascidos.Abstract
Newborns (NB) have an immature coagulation system, which only regularizes in the first year of life, and may occur later in patients with heart disease. The need for the use of anticoagulant therapy in newborns has increased in recent years, but there are still few studies focused on the pediatric population, which makes it difficult to standardize the drug of choice and adjust the dosage. This is an integrative literature review on anticoagulation therapy in newborns. Thrombosis is an effect that rarely occurs in young patients, the group most associated with this event (among young people) are newborns. Among the drugs with anticoagulant action, the most used in this age group is heparin, as it is the drug with the most studies proving the best action and safety of these drugs. However, there is still a difficulty in using this drug, because they act by binding plasma proteins, and these are reduced in newborns. Heparin is strongly associated with adverse effects in the pediatric population, which is why several studies have been conducted to evaluate the effectiveness of the use of oral anticoagulants, such as warfarin and dabigatran. There are few studies that address anticoagulation in pediatrics, and the studies that exist on the subject only address heparin. There are ongoing studies that use oral drugs and which bring expectations of the release of the use of these drugs for the pediatric age group in the coming years.
Downloads
References
BINGHAM, K. R.; RILEY, J. B.; SCHEARS, G. J. Anticoagulant management during first five days of infant-pediatric extracorporeal life suport. The journal of the Extracorporeal technology, v. 50, p. 30-37, 2018.
BRUSCHETTINI, M.; ROMANTSIK, O.; ZAPPETTINI, S.; BANZI, R.; RAMENGHI, L. A.; CALEVO, M. G. Antithrombin for the prevention of intraventricular hemorrhage in very preterm infants (Review). The Cocharane Database of Systematic Reviews, 2016a.
BRUSCHETTINI, M.; ROMANTSIK, O.; ZAPPETTINI, S.; BANZI, R.; RAMENGHI, L. A.; CALEVO, M. G. Heparin for the prevention of intraventricular hemorrhage in preterm infants (Review). The Cocharane Database of Systematic Reviews, 2016b.
DIETRICH, K.; STANG, L.; VAN RYN, J.; MITCHELL, L. G. Assessing the anticoagulant effect of dabigatran in children: an a vitro study. Thrombosis Research, v. 135, p 630-635, 2015.
EMANI, S.; ZURAKOWSKI, D.; BAIRD, C. W.; PIGULA, F. A.; TRENOR III, C.; EMANI, S. M. Hypercoagulability panel testing predicts thrombosis in neonates undergoing cardiac surgery. American Journal of Hematology, v. 89, n. 2, 2014.
GIUFFRÈ, M.; LO VERSO, C.; SERRA, G.; MOCERI, G.; CIMADOR, M.; CORSELLA, G. Portal vein thrombosis in a preterm newborn with mutation of the MTHFR and PAI-1 genes and sepsis by Candida parapsilosis. American Journal of Perinatology, v. 33, n. 11, 2016.
GREENE, L. A.; LAW, C.; JUNG, M.; WALTON, S.; IGNAJATOVIC, V.; MONAGLE, P.; RAFFINI, L. J. Lack of anti-factor Xa assay standardization results in signification low molecular weight heparin (enoxaparin) dose variation in neonates and children. Journal of thrombosis and haemostasis, v. 12, 2014.
ICHIYAMA, M.; INOUE, H.; OCHIAI, M.; ISHIMURA, M.; SHIRAISHI, A.; FUJIYOSHI, J.; YAMASHITA, H.; SATO, K.; MATSUMOTO, S.; HOTTA, T.; UCHIUMI, T.; KANG, D.; OHGA, S. Diagnostic challenge of the newborn patients with heritable protein C deficiency. Journal of Perinatology, v. 39, p. 212-219, 2019.
KAMDAR, A.; RINTOUL, N.; RAFFINI, L. Anticoagulant in neonatal ECMO. Seminars in perinatology, 2017.
KARLAFITS, V.; SRITHARAN, G.; ATTARD, C.; CORRAL, J.; MONAGLE, P; IGNJATOVIC, V. Beta-antithrombotic activity in chlidren and adults: implications for heparin therapy in infants and children. Journal of Thrombosis and haemostasis, v. 12, p. 1141-1144, 2014.
MALE, C.; MONAGLE, P.; CHAN, A. K. C.; YOUNG, G. Recommendations for the development of the new anticoagulant drugs for pediatric use: communication for then SSC of the ISTH. Journal of Thrombosis and haemostasis, v. 13, p. 481-484, 2015.
MANLHIOT, C.; GRUENWALD, C. E.; HOLTBY, H. M.; BRANDÃO, L. R.; CHAN, A. K.; VAN ARSDELL, G. S.; MCCRINDLE, B. W. Challenges with heparina based anticoagulante during cardiopulmonar bypass em childrens: Impacts of low antithrombin activity. The jornal of Thoracic and Cardiovascular Surgery, 2016.
MURPHY, C. A.; NEARY, E.; O’REALLY, D. P.; CULLIVAN, S.; EL-KHUFFASH, A.; NIAINLINE, F.; MAGUIRE, P. B.; MCCALLION, N.; KEVANE, B. The role of the calibrated automated thrombogram in neonates: describing mechanisms of neonatal naemosthasis and evaluating haemostic drugs. European Jornaul of Pediatrics, v. 181, p. 23-33, 2022.
NAIR, A. G.; OLADUNJOYE, O. O.; TRENOR, C. C.; LARONDE, M.; VAN DEN BOSCH, S. J.; SLEEPER, L. A.; VANDERPLUYM, C.; EMANI, S. M.; KHEIR, J. N. An anticoagulation protocol for use after congenital cardiac surgery. The journal of thoracic and cardiovascular surgery, v. 156, n. 1, 2018.
NEWALL, F.; BRANCHFORD, B.; MALE, C. Anticoagulant prophylaxis and therapy in children: current challenges and emerging issues. Journal of Thrombosis and Haemostasis, v. 16, p. 196-208, 2018.
PETERSON, J. A.; MARONEY, S. A.; ZWIFELHOFER, W.; WOOD, J. P.; YAN, K.; BERCOVITZ, R. S.; WOODS, R. K.; MAST, E. A. Heparin-protomine balance after neonatal cardiopulmonary sugery. J. Thromb Haemost, v. 16, n. 10, p. 1973-1983, 2018.
RAFFAELI, G.; PESENTI, N.; CAVALLARO, G.; CORTESI, V.; MANZONI, F.; AMELIO, G. S.; GULDEN, S.; NAPOLITANO, L.; MACCHINI, F.; MOSCA, F.; GHIRARDELLO, S. Optimizing fresh-frozen plasma transfusion in surgical neonates through thromboelastography: a quality improvement study. European Journal of Pediatrics, v. 181, 2022.
SILVA, C. M. C.; AZEVEDO, L. S. N.; CARVALHO, A. C. C. Indicações atuais para anticoagulação em crianças com cardiopatias congênitas. Revista da Sociedade de Cardiologia do Estado de São Paulo, v. 25, n. 3, 2015.
SOCIEDADE PORTUGUESA DE NEONATOLOGIA. Consenso clínico “Trombose neonatal”. [S. l.]: Spciedade Portuguesa de Neonatologia, 2018.
SOUSA, T. C. Heparina: um estudo da literatura sobre características, propriedades físico-químicas e métodos aplicados à sua análise. 2022. Trabalho de conclusão de curso Graduação em Farmácia) - Universidade Federal de Goiás, Goiania, 2022.
SULKOWSKI, J. P.; PRESTON, T. J.; COOPER, J. N.; DUFFY, V. L.; DEANS, K. J.; CHICOINE, L. G.; MINNECI, P. C. Comparision of routine laboratory measures heparin anticoagulation for neonates on extracorporeal membrane oxygenation. The journal of extra-corporeal technology, v. 46, 2014.
YOUNG, G.; LENSING, A. W. A.; MONAGLE, P.; MALE, C.; THELEN, K.; WILLIANN, S.; PALUMBO, J. S.; KUMAR, R.; NURMEEV, I.; HEGE, K.; BAJOLLE, F.; CONNOR, P.; HOOIMEIJER, H. L.; TORRES, M.; CHAN, A. K. C.; KENET, G.; HOLZHAUNER, S.; SANTAMARÍA, A.; AMEDRO, P.; BEYER-WESTENDORF, J.; MARTINELLI, I.; MASSICOTTE, M. P.; SMITH, W. T.; BERKOWITZ, S. D.; SCHIMIDT, S.; PRICE, V.; PRINS, M. H.; KUBITZA, D. Rivaroxaban or treatment of pediatric venous thromboembolism an Einstein Jr phase 3 dose-exposure response evaluation. Journal of Thrombosis and Haemostasis, v. 18, n. 7, 2020. p.1672-1685.
Downloads
Published
How to Cite
License
Copyright (c) 2023 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
This work is licensed under a Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.
